Evidence map›Paper›PMID 37686661›Full record

ReviewCancers2023

Toll-like Receptor Agonists Are Unlikely to Provide Benefits in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Sainiteesh Maddineni, Michelle Chen, Fred Baik, Vasu Divi, John B Sunwoo, Andrey Finegersh

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sainiteesh MaddineniDivision of Head and Neck Surgery, Department of Otolaryngology, School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-4152-273X
Michelle ChenDivision of Head and Neck Surgery, Department of Otolaryngology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Fred BaikDivision of Head and Neck Surgery, Department of Otolaryngology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Vasu DiviDivision of Head and Neck Surgery, Department of Otolaryngology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
John B SunwooDivision of Head and Neck Surgery, Department of Otolaryngology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Andrey FinegershDivision of Head and Neck Surgery, Department of Otolaryngology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Stanford University · USVA Palo Alto Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) has poor survival rates. Immunotherapy is the standard of care for R/M HNSCC, but objective responses occur in a minority of patients. Toll-like receptor (TLR) agonists promote antitumor immune responses and have been explored in clinical trials.

methodsA search for clinical trials using TLR agonists in HNSCC was performed under PRISMA guidelines. Data on patient characteristics, safety, and efficacy were collected and analyzed.

resultsThree phase 1b trials with 40 patients and three phase 2 trials with 352 patients studying TLR8 and TLR9 agonists in combination with other treatment regimens for HNSCC were included. In phase 2 trials, there was no significant change in the objective response rate (RR = 1.13, CI 0.80-1.60) or association with increased grade 3+ adverse events (RR = 0.91, CI 0.76-1.11) associated with TLR agonist use.

conclusionTLR agonists do not appear to provide additional clinical benefits or increase adverse events in the treatment of HNSCC. Given these results across multiple clinical trials and drug regimens, it is unlikely that additional trials of TLR agonists will demonstrate clinical benefits in HNSCC.

Indexed as

head and neck cancerimmunotherapymeta-analysissystematic reviewToll-like receptor

Identifiers

PMID37686661
PMCPMC10486924
OpenAlexW4386421093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.